Axon Enterprise (NASDAQ:AXON) Stock Rating Upgraded by Wall Street Zen

Axon Enterprise (NASDAQ:AXON) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages also recently weighed in on AXON. UBS Group lowered their price target on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research report on Wednesday. TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Citigroup reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday. Finally, Robert W. Baird set a $800.00 price objective on shares of Axon Enterprise in a report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $542.40 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.89 and a current ratio of 2.53. The stock’s 50-day simple moving average is $537.92 and its 200 day simple moving average is $625.54. The company has a market cap of $43.61 billion, a P/E ratio of 356.84, a P/E/G ratio of 16.57 and a beta of 1.48. Axon Enterprise has a 52-week low of $396.41 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. During the same period in the prior year, the firm posted $2.08 earnings per share. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $550.63, for a total value of $55,063.00. Following the transaction, the director directly owned 1,316 shares of the company’s stock, valued at $724,629.08. This trade represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer owned 3,090,997 shares of the company’s stock, valued at approximately $1,546,240,339.28. This represents a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 58,040 shares of company stock worth $32,251,738 in the last quarter. 4.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of the business. NEOS Investment Management LLC grew its holdings in Axon Enterprise by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after acquiring an additional 11,482 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after acquiring an additional 376,904 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Axon Enterprise by 3.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock worth $132,349,000 after purchasing an additional 5,953 shares during the period. BIT Capital GmbH grew its stake in shares of Axon Enterprise by 75.6% in the third quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock worth $2,537,000 after purchasing an additional 1,522 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC grew its stake in shares of Axon Enterprise by 180.7% in the second quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 775 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.